Longest follow-up of HPV vaccination shows enduring protection after 10 years

A 10-year follow-up of 803 sexually inactive boys and girls who received a quadrivalent human papillomavirus vaccine has shown promising results.

Teenager receives quadrivalent HPV vaccine

The long latency period between human papillomavirus (HPV) exposure and the emergence of cervical and genital pre-cancers/cancers means that there is a need for long-term follow-up of vaccinated pre-adolescents and adolescents.

In a study in Pediatrics (online, 1 December 2017), researchers followed up 803 sexually inactive girls and boys (aged 9–15 years) who took part in a placebo-controlled randomised clinical trial of the quadrivalent HPV vaccine[1]

The team found that there were no cases of genital warts or cervical and genital pre-cancers/cancers related to infection with any of the four HPV vaccine types during the 10 years post-vaccination. At 10 years, seropositivity remained high for HPV types 6, 11 and 16 at 89–96%, and was somewhat lower for HPV 18 at 60–79%, consistent with prior studies.

The researchers said the findings supported the durability of HPV vaccine-induced protection, and should encourage expansion of vaccination coverage.


[1] Ferris D, Samakoses R, Block S et al. 4-valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents after 10 years. Pediatrics 2017;140:e20163947. doi: 10.1542/peds.2016-3947

Last updated
Clinical Pharmacist, CP, February 2018, Vol 10, No 2;10(2):DOI:10.1211/PJ.2018.20204190